Salvatore Lo Bue

Fluofarma provides drug discovery through assay design and high content analysis in cells, blood and tissues. The firm’s services include assay development, cell-based screening, drug profiling and MOA, predictive toxicology, in vivo studies and biomarker analysis. It develops technologies designed for automated flow cytometry, confocal microscopy and laser scanning cytometry. The company was founded by François Ichas and Francesca de Giorgi in 2003 and is headquartered in Pessac, France.

Fluofarma provides drug discovery through assay design and high content analysis in cells, blood and tissues. The firm’s services include assay development, cell-based screening, drug profiling and MOA, predictive toxicology, in vivo studies and biomarker analysis. It develops technologies designed for automated flow cytometry, confocal microscopy and laser scanning cytometry. The company was founded by François Ichas and Francesca de Giorgi in 2003 and is headquartered in Pessac, France.

Fluofarma provides drug discovery through assay design and high content analysis in cells, blood and tissues. The firm’s services include assay development, cell-based screening, drug profiling and MOA, predictive toxicology, in vivo studies and biomarker analysis. It develops technologies designed for automated flow cytometry, confocal microscopy and laser scanning cytometry. The company was founded by François Ichas and Francesca de Giorgi in 2003 and is headquartered in Pessac, France.

Fluofarma provides drug discovery through assay design and high content analysis in cells, blood and tissues. The firm’s services include assay development, cell-based screening, drug profiling and MOA, predictive toxicology, in vivo studies and biomarker analysis. It develops technologies designed for automated flow cytometry, confocal microscopy and laser scanning cytometry. The company was founded by François Ichas and Francesca de Giorgi in 2003 and is headquartered in Pessac, France.